Business Description
Centessa Pharmaceuticals PLC
ISIN : US1523091007
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.44 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.3 | |||||
Debt-to-EBITDA | -0.58 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 7.3 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -128.1 | |||||
3-Year EPS without NRI Growth Rate | -118.7 | |||||
3-Year FCF Growth Rate | -123.2 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.13 | |||||
9-Day RSI | 47.57 | |||||
14-Day RSI | 51.48 | |||||
6-1 Month Momentum % | 65.48 | |||||
12-1 Month Momentum % | 127.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 13.29 | |||||
Quick Ratio | 13.29 | |||||
Cash Ratio | 11.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -6.48 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2268.45 | |||||
Net Margin % | -2296.03 | |||||
FCF Margin % | -2157.5 | |||||
ROE % | -61.74 | |||||
ROA % | -42.35 | |||||
ROIC % | -232.43 | |||||
3-Year ROIIC % | -235.12 | |||||
ROC (Joel Greenblatt) % | -1141.39 | |||||
ROCE % | -43.56 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 215.86 | |||||
PB Ratio | 5.96 | |||||
Price-to-Tangible-Book | 6.03 | |||||
EV-to-EBIT | -11.96 | |||||
EV-to-EBITDA | -12.04 | |||||
EV-to-Revenue | 257.79 | |||||
EV-to-FCF | -11.88 | |||||
Price-to-Net-Current-Asset-Value | 7.12 | |||||
Price-to-Net-Cash | 9.46 | |||||
Earnings Yield (Greenblatt) % | -8.36 | |||||
FCF Yield % | -7.41 |